Valuation: Serina Therapeutics, Inc.

Market Cap 56.39M 48.58M 46M 41.7M 78.23M 5.39B 78.62M 546M 210M 2.74B 212M 207M 8.66B P/E 2026 *
-1.41x
P/E 2027 * -1.92x
Enterprise Value 56.39M 48.58M 46M 41.7M 78.23M 5.39B 78.62M 546M 210M 2.74B 212M 207M 8.66B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
49.24%
Yield 2026 *
-
Yield 2027 * -
1 day-11.20%
1 week-18.68%
Current month-8.26%
1 month-22.11%
3 months+20.65%
6 months+43.23%
Current year+16.05%
1 week 2.2
Extreme 2.2
2.78
1 month 2.2
Extreme 2.2
2.92
Current year 1.22
Extreme 1.22
4.08
1 year 1.22
Extreme 1.22
5.83
3 years 1.22
Extreme 1.22
19.93
5 years 1.22
Extreme 1.22
19.93
10 years 1.22
Extreme 1.22
19.93
Date Insider Type Main position Quantity % Market Cap. Importance
22/7/26 Free

Director

30,500 0.2034%
7/7/26 Buy

Director

1,000 0.0067%
26/5/26 Free

Chief Executive Officer

10,100 0.0820%
Change 5-day change 1-year change 3-year change Capi.($)
-11.20%-18.68%-57.23% - 56.39M
-2.11%-1.68%+43.40%+95.58% 66.93B
+1.19%-0.62%+35.42%+76.04% 61.97B
+1.67%+2.47%-11.32%+392.05% 28.26B
+4.55%+1.36%+26.52%+17.28% 24.59B
+0.34%-6.78%-0.01%-14.59% 24.3B
+0.45%-1.82%+18.16%-22.44% 19.41B
-3.03%-2.29%+181.72%+333.47% 16.77B
+3.44%-1.88%-5.46%+547.21% 14.18B
+3.24%-0.31%-7.34%+833.51% 14B
Average -0.15%-4.52%+22.39%+250.90% 27.05B
Weighted average by Cap. +0.56%-2.83%+31.98%+173.23%

Financials

2026 *2027 *
Net sales - -
Net income -28.8M -24.81M -23.5M -21.3M -39.95M -2.75B -40.16M -279M -107M -1.4B -108M -106M -4.42B -29.45M -25.37M -24.03M -21.78M -40.86M -2.81B -41.06M -285M -110M -1.43B -111M -108M -4.52B
Net Debt - -
Logo Serina Therapeutics, Inc.
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
Employees
-
Date Price Change Volume
11/09/26 US$2.220 -11.20% 69,308
10/09/26 US$2.500 -2.72% 68,825
09/09/26 US$2.570 +2.80% 404,459
08/09/26 US$2.500 -8.42% 42,266
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.220USD
Average target price
9.500USD
Spread / Average Target
+327.93%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!